期刊
LUNG CANCER
卷 90, 期 2, 页码 342-345出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2015.08.015
关键词
Lung cancer; Calnexin; Sero-diagnostic marker; Antibody-based proteomics
资金
- JSPS KAKENHI Grant [23590414]
- JST-SENTAN (Development of Systems and Technology for Advanced Measurement and Analysis: Life Innovation Area) program from the Japan Science and Technology Agency
- Japan Society for the Promotion of Science [25-5519]
- Graduate School of Medical Sciences
- School of Allied Health Sciences, Kitasato University [2013-1004]
- Grants-in-Aid for Scientific Research [23590414] Funding Source: KAKEN
To develop sero-diagnostic markers for lung cancer, we generated monoclonal antibodies using lung adenocarcinoma (AC)-derived A549 cells as antigens by employing the random immunization method. Hybridoma supernatants were immunohistochemically screened for antibodies with AMeX-fixed and paraffin-embedded A549 cell preparations. Positive clones were monocloned twice through limiting dilutions. From the obtained monoclonal antibodies, one designated as KU-Lad-001 was recognized as calnexin (CANX) based on immunoprecipitation and MADLI TOF/TOF-MS analysis. To evaluate the utility of this antibody as a sero-diagnostic marker for lung cancer, we performed reverse-phase protein array analysis with samples of 195 lung cancer patients and 100 healthy controls. The CANX expression levels were significantly higher in lung cancer patients than in healthy controls (P < 0.0001), and the area under the curve of ROC was 0.980, with 96.9% specificity and 99.0% sensitivity. Furthermore, since CANX was also detected in stage I disease, the serum CANX levels should be applicable markers discriminating lung cancer patients from healthy controls and possibly used in the detection of early lung cancer. To our knowledge, the present results provide evidence that CANX may be a novel sero-diagnostic marker for lung cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据